Published in Ann Surg on July 01, 1981
Keeping in touch with contact inhibition of locomotion. Trends Cell Biol (2010) 1.85
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24
At least one centimetre for each millimetre. Br Med J (Clin Res Ed) (1984) 1.19
Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am (2011) 0.98
Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol (2013) 0.91
The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg (1984) 0.89
The clinical significance of tumor-infiltrating lymphocytes and microscopic satellites in acral melanoma in a korean population. Ann Dermatol (2013) 0.83
Melanoma epidemiology, biology and prognosis. EJC Suppl (2013) 0.78
Surgery of primary melanomas. Cancers (Basel) (2010) 0.77
At least one centimetre for each millimetre. Br Med J (Clin Res Ed) (1984) 0.75
Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol (2013) 0.75
Limited role for histopathological examination of re-excision specimens of completely excised melanomas. Virchows Arch (2014) 0.75
Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis. Oncogene (2017) 0.75
A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika (1965) 14.16
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg (1970) 12.72
Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer (1975) 3.26
A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg (1978) 2.94
A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery (1979) 2.65
Stage I melanoma of the limbs: assessment of prognosis by levels of invasion and maximum thickness. Tumori (1978) 2.46
The prognostic significance of ulceration of cutaneous melanoma. Cancer (1980) 1.66
Prognostic factors in cutaneous malignant melanoma in stage I. A clinical, morphological and multivariate analysis. Scand J Plast Reconstr Surg (1978) 1.59
A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38
Prognostic index in malignant melanoma. Arch Dermatol (1978) 1.36
A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population. J Bone Joint Surg Am (2001) 7.67
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46
Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med (1974) 4.38
A standardized method for the assessment of shoulder function. J Shoulder Elbow Surg (2009) 4.32
A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst (1995) 4.29
Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol (1992) 4.13
A connective tissue disease screening questionnaire for population studies. Ann Epidemiol (1995) 3.72
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Effect of maternal cigarette smoking on pregnancy complications and sudden infant death syndrome. J Fam Pract (1995) 3.23
Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med (1980) 3.01
GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med (1979) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61
Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates. N Engl J Med (1975) 2.59
Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin (1985) 2.57
Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br (2007) 2.53
Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol (1977) 2.53
Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol (1987) 2.51
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
Ovarian pregnancy and the intrauterine device. Am J Obstet Gynecol (1970) 2.40
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ (2008) 2.36
Melanoma in children. N Engl J Med (1995) 2.35
Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30
Ultraviolet A and melanoma: a review. J Am Acad Dermatol (2001) 2.27
Phototesting and dosimetry for photochemotherapy. Br J Dermatol (1977) 2.17
Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol (1989) 2.14
Evaluation of topical agents that prevent sunburn--superiority of para-aminobenzoic acid and its ester in ethyl alcohol. N Engl J Med (1969) 2.13
Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res (1998) 2.12
Accuracy in the clinical diagnosis of malignant melanoma. Arch Dermatol (1990) 2.10
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Malignant melanoma. A controlled study of possibly associated factors. Arch Dermatol (1969) 2.06
Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06
Lumbar laminectomy alone or with instrumented or noninstrumented arthrodesis in degenerative lumbar spinal stenosis. Patient selection, costs, and surgical outcomes. Spine (Phila Pa 1976) (1997) 2.01
Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol (1994) 2.01
Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol (1992) 1.94
Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92
Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91
Morbidity and mortality in children associated with the use of tobacco products by other people. Pediatrics (1996) 1.90
Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol (1989) 1.89
Family, peer, and neighborhood influences on academic achievement among African-American adolescents: one-year prospective effects. Am J Community Psychol (1996) 1.89
Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol (1976) 1.89
Surface microscopy of pigmented basal cell carcinoma. Arch Dermatol (2000) 1.88
Cutaneous melanoma mortality among the socioeconomically disadvantaged in Massachusetts. Am J Public Health (1996) 1.88
Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86
Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84
Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest (1994) 1.83
Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82
Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82
Consumption of meat, animal products, protein, and fat and risk of breast cancer: a prospective cohort study in New York. Epidemiology (1994) 1.82
Diet and 20-year mortality from coronary heart disease. The Ireland-Boston Diet-Heart Study. N Engl J Med (1985) 1.81
Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol (1991) 1.80
A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79
Precision of automatic measurements of pigmented skin lesion parameters with a MelaFind(TM) multispectral digital dermoscope. Melanoma Res (2000) 1.78
A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77
An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol (1998) 1.76
Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol (2001) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Solution structure of a baculoviral inhibitor of apoptosis (IAP) repeat. Nat Struct Biol (1999) 1.73
Solar nevogenesis: a surrogate for predicting a rise in incidence of malignant melanoma because of ozone depletion. J Am Acad Dermatol (1993) 1.73
Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73
Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72
Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71
Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am (2001) 1.71
Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70
Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ (2006) 1.70
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Endogenous hormones and breast cancer: a prospective cohort study. Breast Cancer Res Treat (1991) 1.68
Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med (1999) 1.68
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
Use of health services before the diagnosis of melanoma: implications for early detection and screening. J Gen Intern Med (1993) 1.68